Intensifying treatment of type 2 diabetes mellitus: Adding insulin

Pharmacotherapy

Volumn 31, Issue 12 PART 2, 2011, Pages

  Peters, Kyle R ^a,b  

^a Siouxland Community Health Center   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Basal insulin; Basal bolus treatment; Long acting insulin; Metformin; Oral antidiabetic drugs; Rapid acting insulin

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; SULFONYLUREA DERIVATIVE; EXENDIN 4; HUMAN INSULIN; INSULIN DERIVATIVE; LIRAGLUTIDE; ANTIDIABETIC AGENT;

AREA UNDER THE CURVE; BEDTIME DOSAGE; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN INFUSION; INSULIN RELEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PHARMACIST ATTITUDE; PHARMACODYNAMICS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; WEIGHT GAIN; ADD ON THERAPY; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; FOOD INTAKE; HYPERGLYCEMIA; INSULIN PEN; INSULIN PUMP; INSULIN TREATMENT; PHARMACIST; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; PROFESSIONAL STANDARD; STANDARD;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT EDUCATION AS TOPIC; PHARMACISTS; PROFESSIONAL ROLE;

EID: 82655169421     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.12.54S     Document Type: Review

References (85)

1. Dushay J, Abrahamson MJ. Insulin therapy for type 2 diabetes: making it work. J Fam Pract 2010;59:E1-8.
2. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
3. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006;32(1 suppl):9S-18.
4. Eliasson B, Eeg-Olofsson K, Cederholm J, Nilsson PM, Gudbjornsdottir S. Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register. Diabetes Metab 2007;33:269-76. (Pubitemid 47418703)
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
6. Institute for Safe Medication Practices. ISMP's list of high-alert medications. Available from http://www.ismp.org/Tools/highalertmedications.pdf. Accessed March 1, 2011.
7. Swinnen SG, Hoekstra JB, Devries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009;32(suppl 2):S253-9.
8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
9. American Diabetes Association. Insulin (and other injectable drugs). Available from http://forecast.diabetes.org/print/node/897. Accessed May 18, 2011.
10. Ligthelm R, Davidson J. Initiating insulin in primary care - the role of modern premixed formulations. Prim Care Diabetes 2008;2:9-16.
11. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 2009;14:373-9.
12. Teuscher A, ed. The history of insulin. In: Insulin: a voice for choice. Basel, Switzerland: Karger, 2007:10-13.
13. White JR. Insulin analogs: what are the clinical implications of structural differences? US Pharmacist 2010;35(diabetes suppl):3-7.
14. Ganiats TG. Variability in insulin action: mechanisms, implications, and recent advances [online exclusive article]. Internet J Fam Prac 2007;5. Available from http://www.ispub.com/journal/the-internet-journal-of-family- practice/volume-5-number-2-12/article/variability-in-insulin-action-mechanisms- implications-and-recent-advances.html.
15. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008;47:7-20. (Pubitemid 350260885)
16. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the longacting insulin analog detemir. Diabetes Care 2005;28:1107-12. (Pubitemid 40616620)
17. Wutte A, Plank J, Bodenlenz M, et al. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007;115:461-7. (Pubitemid 47234648)
18. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008;6:54-67.
19. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-9. (Pubitemid 46502046)
20. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-59. (Pubitemid 47261846)
21. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 2004;328:274-80. (Pubitemid 39518531)
22. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81. (Pubitemid 44856694)
23. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8.
24. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6. (Pubitemid 37339502)
25. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9.
26. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74. (Pubitemid 44125921)
27. Flood TM. Appropriate use of insulin analogs in an increasingly complex type 2 diabetes mellitus (T2DM) landscape. J Fam Pract 2007;56:S1-10.
28. Novo Nordisk Inc. Levemir (insulin detemir [rDNA origin] injection) package insert. Princeton, NJ; 2009.
29. sanofi-aventis. Lantus (insulin glargine [rDNA origin] injection) package insert. Bridgewater, NJ; 2010.
30. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87.
31. Swinnen SG, Dain MP, Mauricio D, Devries JH, Hoekstra JB, Holleman F. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes Obes Metab 2010;12:923-5.
32. Meneghini L, Koenen C, Weng W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 algorithm) for insulin detemir in patients with type 2 diabetes - results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab 2007;9:902-13. (Pubitemid 47555212)
33. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27. (Pubitemid 46502062)
34. Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab 2009;11:623-31.
35. King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab 2009;11:69-71.
36. Fakhoury W, Lockhart I, Kotchie RW, Aagren M, Lereun C. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology 2008;82:156-63.
37. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemirbased basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009;63:425-32.
38. Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS ONE 2009;4:e6112 [online exclusive article]. Available from dx.doi.org/10.1371/ journal.pone.0006112.
39. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) - a proof-of-concept study. Diabetes Care 2010;33:1509-15.
40. Anholm C, Frandsen H, Hojgaard-Hansen EC, Vestergaard H, Madsbad S. Use of once daily liraglutide in type 2 diabetes: clinical practice and experiences from combination with oral antidiabetic drugs or insulin [abstract]. Diabetes 2011;60(suppl 1):A314.
41. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30. (Pubitemid 350005153)
42. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47.
43. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. Med Gen Med 2007;9:12.
44. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9:630-9. (Pubitemid 47261844)
45. American Diabetes Association. Practical insulin: a handbook for prescribing providers. Alexandria, VA: American Diabetes Association, 2002.
46. Novo Nordisk Inc. NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin]) package insert. Princeton, NJ; 2010.
47. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006;8:58-66.
48. Rochester CD, Leon N, Dombrowski R, Haines ST. Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2010;67:42-8.
49. Shah S, Benroubi M, Borzi V, et al. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract 2009;63:623-31.
50. The Insulin Dependent Diabetes Trust. 30 years of synthetic insulin, are people with diabetes getting the best deal? A report of patients' concerns. Available from http://www.iddt.org/wp-content/uploads/2009/10/30-year-report- oct-2007.pdf. Accessed March 1, 2011.
51. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-82. (Pubitemid 35283332)
52. Pampanelli S, Torlone E, Ialli C, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995;18:1452-9.
53. Brunelle RL, Llewelyn J, Anderson JH Jr., Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-31. (Pubitemid 28449815)
54. Lalli C, Ciofetta M, Del SP, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77. (Pubitemid 29106907)
55. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract 2001;55:177-82. (Pubitemid 32390155)
56. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9. (Pubitemid 38658363)
57. Nosek L, Becker RH, Frick AD, Kapitza C, Heise T, Rave K. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin [abstract]. Diabetes 2004;53(suppl 2):39-40.
58. Garg S, Rosenstock J, Ways K. Efficacy and safety of post-meal insulin glulisine (GLU) compared with pre-meal regular human insulin (RHI) in a basal-bolus regimen with insulin glargine [abstract]. Diabetes 2004;53(suppl 2):125.
59. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363-8. (Pubitemid 39281386)
60. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52.
61. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes, previously treated with glargine plus oral agents: prandial premixed (lispro/ILPS) vs. basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5.
62. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(suppl 1):S11-61.
63. Bode BW. Medical management of type 1 diabetes, 4th ed. Alexandria, VA: American Diabetes Association, 2004.
64. Walsh JA, Roberts R, Bailey T, Varma CB. Using insulin: everything you need for success with insulin. San Diego, CA: Torrey Pines Press, 2003.
65. Kroon L. Overview of insulin delivery pen devices. J Am Pharm Assoc (2003) 2009;49:e118-31.
66. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(suppl 2):S140-5.
67. Segal AR, Brunner JE, Burch FT, Jackson JA. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 2010;67:1526-35.
68. Cochran E, Gorden P. Use of U-500 insulin in the treatment of severe insulin resistance. Insulin 2011;3:211-18.
69. Drab S. Translating clinical guidelines into clinical practice: role of the pharmacist in type 2 diabetes management. J Am Pharm Assoc (2003) 2009;49:e152-62.
70. Vivian EM. The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus. Consult Pharm 2007;22:320-32. (Pubitemid 351729255)
71. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother 1998;32:636-41. (Pubitemid 28283846)
72. Eli Lilly and Company. Humulin R (regular insulin human injection, USP [rDNA origin] 100 units per mL [U-100]) package insert. Indianapolis, IN; 2011.
73. Eli Lilly and Company. Humulin R (regular U-500 [concentrated] insulin human injection [rDNA origin]) package insert. Indianapolis, IN; 2011.
74. Novo Nordisk Inc. NovoLog (insulin aspart [rDNA origin] injection) package insert. Princeton, NJ; 2010.
75. Eli Lilly and Company. Humalog (insulin lispro injection, USP) package insert. Indianapolis, IN; 2011.
76. sanofi-aventis. Apidra (insulin glulisine) package insert. Bridgewater, NJ; 2009.
77. Eli Lilly and Company. Humulin 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin] 100 units per mL [U-100]) package insert. Indianapolis, IN; 2007.
78. Eli Lilly and Company. Humalog Mix 75/25™ (75% insulin lispro protamine suspension and 25% insulin lispro injection [rDNA origin]) package insert. Indianapolis, IN; 2009.
79. Eli Lilly and Company. Humalog Mix 50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin]) package insert. Indianapolis, IN; 2009.
80. Eli Lilly and Company. Humulin N (NPH human insulin isophane suspension [rDNA origin]) package insert. Indianapolis, IN; 2009.
81. Novo Nordisk Inc. Novolin N (NPH human insulin isophane suspension [rDNA origin]) package insert. Princeton, NJ; 2010.
82. Novo Nordisk Inc. Novolin R (regular human insulin [rDNA origin]) package insert. Princeton, NJ; 2010.
83. Eli Lilly and Company. Humulin 70/30 pen information for the patient. Indianapolis, IN; 2009.
84. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34. (Pubitemid 33051266)
85. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007;21:220-6. (Pubitemid 47002315)